A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)
PURPOSE: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. METHODS: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. RESULTS: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0-I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. CONCLUSION: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.
Authors
- Andrew David Redfern (ORCID: https://orcid.org/0000-0001-6728-8713)
- Janine Margaret Lombard (ORCID: https://orcid.org/0000-0002-9551-0542)
- Sherene Loi (ORCID: https://orcid.org/0000-0001-6137-9171)
- Rebecca Asher (ORCID: https://orcid.org/0000-0003-2502-4693)
- Nicholas Zdenkowski (ORCID: https://orcid.org/0000-0001-8738-8463)
- Val Gebski (ORCID: https://orcid.org/0000-0001-8748-1844)
- Benjamin Frederik Dessauvagie (ORCID: https://orcid.org/0000-0001-8899-8925)
- Clair Shadbolt (ORCID: https://orcid.org/0000-0001-8117-4026)
- Prudence A. Francis (ORCID: https://orcid.org/0000-0002-7207-9286)
- Cameron Edward Snell (ORCID: https://orcid.org/0000-0001-7847-3041)
- Luis E. Lara Gonzalez (ORCID: https://orcid.org/0000-0003-3897-353X)
- Nicholas Wilcken (ORCID: https://orcid.org/0000-0003-4006-0289)
- Courtney T. van Geelen (ORCID: https://orcid.org/0000-0002-2716-9135)
- Frances M. Boyle (ORCID: https://orcid.org/0000-0003-3798-1570)
- Wendy A. Raymond (ORCID: https://orcid.org/0000-0003-4422-2345)
- Núria Chic (ORCID: https://orcid.org/0000-0001-9736-6276)
- Franco Caramia (ORCID: https://orcid.org/0000-0002-5086-2544)
- Andrew John Spillane (ORCID: https://orcid.org/0000-0002-8354-434X)
- J. Kay (ORCID: https://orcid.org/0009-0009-6673-6604)
- Nicholas Murray (ORCID: https://orcid.org/0009-0002-0044-8406)
- Heath Badger (ORCID: https://orcid.org/0009-0009-0606-0534)
- Susan Tiley
Institutions
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- The University of Western Australia (AU)
- Peter MacCallum Cancer Centre (AU)
- Fiona Stanley Hospital (AU)
- Gosford Hospital (AU)
- Flinders Medical Centre (AU)
- Westmead Hospital (AU)
- Breast Cancer Trials (AU)
- St Vincent’s Private Hospital Sydney (AU)
- Calvary Mater Newcastle Hospital (AU)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0501
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00